A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus

Journal of Virology

Volumn 82, Issue 14, 2008, Pages 6927-6934

  Raviprakash, Kanakatte ^a,b   Wang, Danher ^d   Ewing, Dan ^a   Holman, David H ^d   Block, Karla ^a   Woraratanadharm, Jan ^d   Chen, Lan ^a   Hayes, Curtis ^a   Dong, John Y ^c,d   Porter, Kevin ^a,b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d GenPhar Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DENGUE VACCINE; ENVELOPE PROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS; FEMALE; INFECTION PREVENTION; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VACCINATION; VIREMIA; ADENOVIRUS; ANIMAL; BLOOD; DENGUE; GENE VECTOR; GENETICS; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MACACA; SERODIAGNOSIS;

ADENOVIRIDAE; ANIMALIA; DENGUE VIRUS; DENGUE VIRUS GROUP; MACACA MULATTA;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; GENETIC VECTORS; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; NEUTRALIZATION TESTS; VIRAL STRUCTURAL PROTEINS; VIREMIA;

EID: 47049129455     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02724-07     Document Type: Article

References (39)

1. Blaney, J. E., Jr., C. T. Hanson, K. A. Hanley, B. R. Murphy, and S. S. Whitehead. 2004. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4:39.
2. Blaney, J. E., Jr., J. M. Matro, B. R. Murphy, and S. S. Whitehead. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516-5528.
3. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
4. Chen, L., D. Ewing, H. Subramanian, K. Block, J. Rayner, K. D. Alterson, M. Sedegah, C. Hayes, K. Porter, and K. Raviprakash. 2007. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J. Virol. 81:11634-11639.
5. Cohen, P. 2006. Immunity's yin and yang. A successful vaccine must first avoid being eliminated by pre-existing immunity before it can promote a protective immune response. IAVI Rep. 10:1-5.
6. de Silva, A., and W. Messer. 2004. Arguments for live flavivirus vaccines. Lancet 364:500.
7. Edelman, R., S. S. Wasserman, S. A. Bodison, R. J. Putnak, K. H. Eckels, D. Tang, N. Kanesa-Thasan, D. W. Vaughn, B. L. Innis, and W. Sun. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60.
8. Gould, E. A., S. R. Moss, and S. L. Turner. 2004. Evolution and dispersal of cncephalitic flaviviruses. Arch. Virol. Suppl. 18:65-84.
9. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
10. Guirakhoo, F., S. Kitchener, D. Morrison, R. Forrat, K. McCarthy, R. Nichols, S. Yoksan, X. Duan, T. H. Ermak, N. Kanesa-Thasan, P. Bedford, J. Lang, M. J. Quentin-Millet, and T. P. Monath. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2:60-67.
11. Guirakhoo, F., K. Pugachev, Z. Zhang, G. Myers, I. Levenbook, K. Draper, J. Lang, S. Ocran, F. Mitchell, M. Parsons, N. Brown, S. Brandler, C. Fournier, B. Barrere, F. Rizvi, A. Travassos, R. Nichols, D. Trent, and T. Monath. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761-4775.
12. Hahn, C. S., S. Lustig, E. G. Strauss, and J. H. Strauss. 1988. Western equine encephalitis virus is a recombinant virus. Proc. Natl. Acad. Sci. USA 85:5997-6001.
13. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
14. Halstead, S. B., J. Casals, H. Shotwell, and N. Palumbo. 1973. Studies on the immunization of monkeys against dengue. I. Protection derived from single and sequential virus infections. Am. J. Trop. Med. Hyg. 22:365-374.
15. Halstead, S. B., and N. E. Palumbo. 1973. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am. J. Trop. Med. Hyg. 22:375-381.
16. Holman, D. H., D. Wang, K. Raviprakash, N. U. Raja, M. Luo, J. Zhang, K. R. Porter, and J. Y. Dong. 2007. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin. Vaccine Immunol. 14:182-189.
17. Hombach, J., I. Kurane, and D. Wood. 2004. Arguments for live flavivirus vaccines. Lancet 364:498-499.
18. IAVI News. 5 February 2008, posting date. Further analysis of STEP AIDS vaccine trial reaffirms earlier trend. http://www.iavi.org/viewfile.cfm? fid=47758.
19. Innis, B. L. 1997. Antibody responses to dengue virus infection, p. 221-243. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, New York, NY.
20. Kitchener, S., M. Nissen, P. Nasveld, R. Forrat, S. Yoksan, J. Lang, and J. F. Saluzzo. 2006. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24:1238-1241.
21. Kliks, S. C., S. Nimmanitya, A. Nisalak, and D. S. Burke. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
22. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
23. Kochel, T. J., K. Raviprakash, C. G. Hayes, D. M. Watts, K. L. Russell, A. S. Gozalo, I. A. Phillips, D. F. Ewing, G. S. Murphy, and K. R. Porter. 2000. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 18:3166-3173.
24. Koraka, P., S. Benton, G. van Amerongen, K. J. Stittelaar, and A. D. Osterhaus. 2007. Efficacy of a live attenuated tetravalent candidate dengue vaccine in naive and previously infected cynomolgus macaques. Vaccine 25:5409-5416.
25. Murphy, B. R., J. E. Blaney, Jr., and S. S. Whitehead. 2004. Arguments for live flavivirus vaccines. Lancet 364:499-500.
26. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
27. Putnak, J. R., B. A. Coller, G. Voss, D. W. Vaughn, D. Clements, I. Peters, G. Bignami, H. S. Houng, R. C. Chen, D. A. Barvir, J. Seriwatana, S. Cayphas, N. Garcon, D. Gheysen, N. Kanesa-Thasan, M. McDonell, T. Humphreys, K. H. Eckels, J. P. Prieels, and B. L. Innis. 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23:4442-4452.
28. Putnak, R., D. A. Barvir, J. M. Burrous, D. R. Dubois, V. M. D'Andrea, C. H. Hoke, J. C. Sadoff, and K. H. Eckels. 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174:1176-1184.
29. Raviprakash, K., K. R. Porter, T. J. Kochel, D. Ewing, M. Simmons, I. Phillips, G. S. Murphy, W. R. Weiss, and C. G. Hayes. 2000. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J. Gen. Virol. 81:1659-1667.
30. Rigau-Perez, J. G., G. G. Clark, D. J. Gubler, P. Reiter, E. J. Sanders, and A. V. Vorndam. 1998. Dengue and dengue haemorrhagic fever. Lancet 352:971-977.
31. Sabchareon, A., J. Lang, P. Chanthavanich, S. Yoksan, R. Forrat, P. Attanath, C. Sirivichayakul, K. Pengsaa, C. Pojjaroen-Anant, W. Chokejindachai, A. Jagsudee, J. F. Saluzzo, and N. Bhamarapravati. 2002. Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. Am. J. Trop. Med. Hyg. 66:264-272.
32. Scott, R. M., S. Nimmannitya, W. H. Bancroft, and P. Mansuwan. 1976. Shock syndrome in primary dengue infections. Am. J. Trop. Med. Hyg. 25:866-874.
33. Seligman, S. J., and E. A. Gould. 2004. Live flavivirus vaccines: reasons for caution. Lancet 363:2073-2075.
34. Shiver, J. W., T. M. Fu, L. Chen, D. R. Casimire, M. E. Davies, R. K. Evans, Z. Q. Zhang, A. J. Simon, W. L. Trigone, S. A. Dubey, L. Huang, V. A. Harris, R. S. Long, X. Liang, L. Handt, W. A. Schleif, L. Zhu, D. C. Freed, N. V. Persaud, L. Guan, K. S. Punt, A. Tang, M. Chen, K. A. Wilson, K. B. Collins, G. J. Heidecker, V. R. Fernandez, H. C. Perry, J. G. Joyce, K. M. Grimm, J. C. Cook, P. M. Keller, D. S. Kresock, H. Mach, R. D. Troutman, L. A. Isopi, D. M. Williams, Z. Xu, K. E. Bohannon, D. B. Volkin, D. C. Montefiori, A. Miura, G. R. Krivulka, M. A. Lifton, M. J. Kuroda, J. E. Schmitz, N. L. Letvin, M. J. Caulfield, A. J. Bett, R. Youil, D. C. Kaslow, and E. A. Emini. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
35. Sun, W., R. Edelman, N. Kanesa-Thasan, K. H. Eckels, J. R. Putnak, A. D. King, H. S. Houng, D. Tang, J. M. Scherer, C. H. Hoke, Jr., and B. L. Innis. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69:24-31.
36. Sun, W., A. Nisalak, M. Gettayacamin, K. H. Eckels, J. R. Putnak, D. W. Vaughn, B. L. Innis, S. J. Thomas, and T. P. Endy. 2006. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J. Infect. Dis. 193:1658-1665.
37. Twiddy, S. S., and E. C. Holmes. 2003. The extent of homologous recombination in members of the genus Flavivirus. J. Gen. Virol. 84:429-440.
38. Wang, D., M. Hevey, L. Y. Juompan, C. M. Trubey, N. U. Raja, S. B. Deitz, J. Woraratanadharm, M. Luo, H. Yu, B. M. Swain, K. M. Moore, and J. Y. Dong. 2006. Complex adenovirus-vectored vaccine protects guinea pigs from three strains of Marburg virus challenges. Virology 353:324-332.
39. Wang, D., N. U. Raja, C. M. Trubey, L. Y. Juompan, M. Luo, J. Woraratanadharm, S. B. Deitz, H. Yu, B. M. Swain, K. M. Moore, W. D. Pratt, M. K. Hart, and J. Y. Dong. 2006. Development of a cAdVax-based bivalent Ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus. J. Virol. 80:2738-2746.